

Alain P Algazi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/754299/alain-p-algazi-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

11,796
citations

31
h-index

63
g-index

63
ext. papers

14,192
ext. citations

13.6
avg, IF

5.44
L-index

#	Paper	IF	Citations
57	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. <i>New England Journal of Medicine</i> , 2013 , 369, 134-44	59.2	2661
56	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>New England Journal of Medicine</i> , 2012 , 367, 1694-703	59.2	2048
55	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2012 , 13, 1087-95	21.7	708
54	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2019 , 393, 156-167	40	674
53	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1600-9	27.4	666
52	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018 , 379, 722-730	59.2	659
51	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. <i>Immunity</i> , 2018 , 49, 1148-1161.e7	32.3	352
50	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. <i>Journal of Clinical Investigation</i> , 2016 , 126, 3447-52	15.9	325
49	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015 , 47, 250-6	36.3	320
48	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. <i>JAMA Dermatology</i> , 2015 , 151, 1206-1212	5.1	305
47	Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space. <i>Electroencephalography and Clinical Neurophysiology</i> , 1992 , 82, 356-68		282
46	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017 , 5, 417-424	12.5	241
45	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. <i>Cancer Cell</i> , 2015 , 27, 240-56	24.3	226
44	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016 , 34, 871-8	2.2	206
43	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016 , 122, 3344-3353	6.4	199
42	Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli. <i>Electroencephalography and Clinical Neurophysiology</i> , 1992 , 82, 341-55		186
41	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018 , 553, 347-350	50.4	178

40	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 450-73	7.3	165
39	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016 , 122, 3354-3362	6.4	164
38	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3697-704	2.2	158
37	Processing of auditory stimuli during auditory and visual attention as revealed by event-related potentials. <i>Psychophysiology</i> , 1994 , 31, 469-79	4.1	129
36	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3003-3003	2.2	94
35	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1083-1088	2.7	88
34	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. <i>British Journal of Cancer</i> , 2017 , 116, 1141-1147	8.7	80
33	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 945-58	7.3	66
32	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 643-654	21.7	58
31	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 665-74	4.6	54
30	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 1910-1919	12.9	48
29	Brain potential signs of feature processing during auditory selective attention. <i>NeuroReport</i> , 1991 , 2, 189-92	1.7	46
28	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 2827-2837	12.9	43
27	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). <i>Immunotherapy</i> , 2017 , 9, 1309-1321	3.8	35
26	Treatment of cutaneous melanoma: current approaches and future prospects. <i>Cancer Management and Research</i> , 2010 , 2, 197-211	3.6	29
25	Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018 , 31, 110-114	4.5	28
24	Biology and treatment of primary central nervous system lymphoma. <i>Neurotherapeutics</i> , 2009 , 6, 587-976.	6.4	28
23	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. <i>Cancer Immunology Research</i> , 2020 , 8, 246-254	12.5	27

22	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020 , 26, 1564-1568	50.5	27
21	Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	24
20	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021 , 23, 1961-1973	19.73	24
19	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 1692-1704	21.7	23
18	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020 , 11, 6262	17.4	20
17	Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. <i>Laryngoscope</i> , 2020 , 130, E48-E56	3.6	17
16	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. <i>Cancer Cell</i> , 2021 , 39, 1375-1387.e6	24.3	16
15	Head and neck cancer in 2016: A watershed year for improvements in treatment?. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 76-78	19.4	15
14	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019 , 32, 603-606	4.5	11
13	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 655-664	21.7	9
12	Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. <i>Head and Neck</i> , 2019 , 41, E82-E85	4.2	9
11	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 781-796	7.1	5
10	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4122-4130	3.1	5
9	SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2576-2576	2.2	5
8	Relationship between liver metastases and PD-1 blockade in melanoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3072-3072	2.2	3
7	Sexual activity and function in male cancer patients receiving targeted an immune therapies.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21594-e21594	2.2	1
6	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 78-78	2.2	1
5	New horizons in melanoma treatment: targeting molecular pathways. <i>Ochsner Journal</i> , 2010 , 10, 93-8	1.5	1

4	Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
3	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.. <i>Molecular Therapy - Oncolytics</i> , 2022 , 25, 174-188	6.4	0
2	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9558-9558	2.2	
1	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21593-e21593	2.2	